Ozempic Fuels Hunt for Smaller Clothes

Apparel retailers are discovering that weight loss is their gain.

While blockbuster drugs like Ozempic that lead to significant weight loss have dented demand for diet plans and caused food companies to prepare for people eating less, clothing sellers are finding that millions of slimmed-down Americans want to buy new clothes.

The newly svelte aren’t just restocking their wardrobes, many are also gravitating to more body-hugging shapes and risqué designs, according to industry executives and shoppers. Some brands are responding by replacing zippers with adjustable corsets and adding more sheer looks.

The nascent downsizing is happening across brands and types of garments. Industry executives said that they can’t be certain weight-loss medicine is the cause, but added that the shift is unlike anything they have seen. It is also an about-face from recent years, when many retailers rushed to add larger sizes to accommodate Americans’ growing girth.

About 5% of Lafayette 148’s customers are buying new outfits because they have lost weight, often replacing their size 12 clothes with size 6 or 8, according to Deirdre Quinn , the brand’s chief executive. The benefit is twofold; in addition to boosting sales, Lafayette 148 is saving money because smaller sizes use less fabric, Quinn said.

More customers of clothing rental company Rent the Runway are switching to smaller sizes than at any time in the past 15 years, said Jennifer Hyman , co-founder and CEO. These customers are also showing more of a willingness to experiment with different styles such as cutouts and other body-baring features. “When you are more comfortable in your skin, you are more willing to try edgier looks,” she said.

For Maggie Rezek, getting dressed used to be about hiding her extra weight in oversize shirts and baggy pants. Since she lost 60 pounds on semaglutide, the active ingredient in Ozempic, the 32-year-old, who handles marketing for a beauty salon, has splurged on a new wardrobe. Now, her staples consist of crop tops and jean shorts. She has traded in her sneakers for kitten heels. She even documents her outfits on social media.

“Before, I was insecure about my body,” said Rezek, who lives in Indianapolis. “Now, I feel like I fit better in clothes. That gives me the confidence to dress up and be more stylish.”

Some 15.5 million people, or 6% of U.S. adults, say they have tried injectable weight loss drugs to slim down, according to a survey of more than 5,500 Americans conducted in March by polling company Gallup. Nearly three-quarters of current users said the drugs—a class known as GLP-1 that were originally developed to treat diabetes—are effective or extremely effective in helping them shed pounds.

Weight-loss drugs don’t work for everyone and the cost can sometimes exceed $1,000 a month, limiting the market. The full price isn’t always covered by insurance. Moreover, people struggle to keep the weight off once they stop using the drugs.

Still, some companies expect the market for these drugs will be big enough that they are shifting course. WW International , formerly known as Weight Watchers, acquired a subscription service that offers telehealth visits with doctors who can prescribe drugs like Ozempic. Nestlé is introducing a new food line this year designed for people taking weight-loss medication.

Clothing companies could use a boost. Apparel sales fell 4% in the 12 months that ended in April compared with the same period a year earlier, according to market research firm Circana, as people give priority to their spending on necessities.

Coming out of the Covid-19 pandemic, Amarra, which sells evening gowns and other formal wear in 800 retailers in the U.S., Canada and Australia, saw increased demand for larger sizes. Now, that trend has reversed.

“Over the past year, our retailers have been telling us they need smaller sizes,” said Abhi Madan, Amarra’s co-founder and creative director. Amarra, which is based in Freehold, N.J., has added sizes as small as 000. He says he is also selling more sizes in the 0-8 range and fewer in the plus-size range of 18-24.

Madan said the shift is changing the way Amarra designs dresses. It is replacing zippers with lace-up corsets, which can more easily accommodate shifting weights because the laces can be tightened or loosened. It is also adding more sheer side panels that give a figure-hugging look.

AllStar Logo, which sells polo shirts, fleece jackets and other gear to large companies, has seen demand for its largest sizes fall by half over the past year, according to Edmond Moss , its sales director.

“We used to sell a lot of fleece jackets in extra, extra large,” Moss said. “Now everything has gone down by at least one size.”

Sales of the three largest sizes of women’s button-down shirts fell 10.9% in the first three months of 2024 compared with the same period in 2022 at a dozen brands, according to Impact Analytics, which helps retailers manage their inventory and size allocations.

Sales of those same button-down shirts in the three smallest sizes grew 12.1% over that period. Impact Analytics analysed purchases in physical stores located on Manhattan’s Upper East Side. It focused its research on this area because it has the highest concentration of individuals in New York City taking these drugs specifically for weight loss, according to market research firm Trilliant Health.

A similar trend played out for women’s dresses and sweaters, as well as men’s polo shirts, sweatshirts and T-shirts, according to Impact Analytics.

Prashant Agrawal , Impact Analytics’ founder and CEO, said it wasn’t possible to know if the size changes resulted from people losing weight or a shift in clothing styles, but added that such a pronounced shift is unusual. “It’s not something we’ve seen before,” he said.

Some executives are worried that the shift could reduce demand for plus-size clothes.

“I’m trying to figure out what we have to worry about in the future,” said Doug Wood , the chief executive of clothing retailer Tommy Bahama, noting that as more people lose weight it could hurt sales of its “Big & Tall” collection designed for very large men.

Jillian Sterba went from a size 6 to a size 10 after the birth of her child. When the weight didn’t come off with diet and exercise, she started injections of semaglutide in October. Since then, Sterba, who is 36 and lives in Austin, has lost 35 pounds. She is now a size 4. “Almost half my clothes are not wearable,” she said.

She bought new jeans, tops, bras and underwear. “I had been wearing flowy tops before but now I’m wearing fitted shirts,” she said. Still, Sterba said she is keeping 80% of her old clothes just in case she gains back the weight.

A sharp technology sell-off has exposed a new anxiety on global markets: whether the enormous borrowing behind the artificial-intelligence infrastructure boom can generate sufficient returns as interest rates rise and Chinese competition intensifies.

The artificial-intelligence investment boom has powered technology shares, semiconductor manufacturers and data-centre operators to extraordinary heights. Last week, investors were given a reminder that much of this expansion is being built with borrowed money.

The technology-heavy Nasdaq Composite fell 4.5 per cent over the week ended October 16, its weakest performance since late June. Semiconductor shares suffered an even deeper correction, with the Philadelphia Semiconductor Index losing about 11.4 per cent.

The selling spread quickly through global markets. Micron Technology fell 14.6 per cent over the week, while South Korea’s Samsung Electronics and SK Hynix dropped approximately 18 per cent and 24 per cent respectively.

This was more than a routine bout of profit-taking. Investors were reassessing three interconnected risks: higher interest rates, the rapidly expanding debt burden attached to AI infrastructure and the prospect of stronger competition from Chinese memory-chip manufacturers.

The debt behind the AI build-out

Artificial intelligence requires a physical infrastructure network of enormous scale. Data centres must be built, advanced processors purchased, power supplies secured and cooling systems installed before customers begin generating meaningful revenue from them.

Technology companies are increasingly supplementing their own cash with corporate bonds, syndicated loans, equipment leases, private credit and project-level financing.

JPMorgan describes the emerging funding model as a combination of conventional corporate borrowing and project finance tied to individual data-centre assets. In Australia, the Reserve Bank estimates that syndicated loans accounted for approximately three-quarters of data-centre financing during 2025 and 2026 to date.

The numbers are becoming large enough to affect broader credit markets. The Federal Reserve Bank of Dallas has cited Wall Street estimates suggesting AI-related investment-grade bond issuance could approach US$300 billion in 2026 alone.

That borrowing is not automatically problematic. Debt can be an efficient way to finance long-lived infrastructure when future revenue is sufficiently predictable. The concern is that AI technology, customer demand and computing economics are changing much faster than the repayment schedules attached to the assets.

A data centre financed today may carry debt for years. Investors must therefore make assumptions about future utilisation rates, electricity prices, chip performance, customer concentration and the amount businesses will ultimately pay for AI computing.

When interest rates rise, those assumptions become less forgiving.

Inflation changes the calculation

September’s US inflation data intensified the pressure. Consumer prices increased 3.7 per cent over the year, ahead of market expectations and up from 3.4 per cent in August.

The hotter reading reduced confidence that interest rates would fall quickly and pushed bond yields higher. That matters particularly for companies whose valuations depend on profits expected well into the future, as well as highly leveraged infrastructure operators that may need to refinance.

CoreWeave has emerged as a closely watched test case. The specialist cloud-computing company has accumulated substantial debt and lease obligations to build AI capacity, while relying on a concentrated group of large technology customers.

Its shares fell sharply during the sell-off, while the cost of insuring its debt against default climbed. CoreWeave has argued that its contracted backlog more than covers its obligations and that financial markets do not always understand its business model. Nevertheless, its securities have become a proxy for investor confidence in debt-funded AI infrastructure.

Oracle, another major investor in AI computing capacity, fell 8.8 per cent in Friday trading, while CoreWeave dropped 15.5 per cent.

The question is shifting from how much AI infrastructure can be built to how profitably it can be operated.

China adds another source of pressure

Interest rates were not the only catalyst. Reports of advances by Chinese memory-chip producer ChangXin Memory Technologies raised concerns that lower-cost Chinese products could increase competition across the global semiconductor industry.

Memory chips are essential to AI systems, but the industry is historically cyclical. Periods of tight supply and high pricing can encourage rapid investment, eventually producing oversupply and falling margins.

The prospect of a well-funded Chinese competitor expanding its technological capabilities unsettled investors in Samsung, SK Hynix and Micron. It also demonstrated that AI-related demand does not insulate chipmakers from conventional competitive pressures.

That combination—slower rate cuts, more expensive financing and potentially cheaper supply—challenged the assumption that every company exposed to AI would enjoy continually expanding margins.

A reset rather than the end of the boom

The sell-off does not establish that the AI boom is ending. Demand for computing power remains strong, the largest technology companies continue to generate formidable cash flows and many infrastructure projects are backed by long-term customer contracts.

What has changed is the market’s willingness to overlook the price and financing structure of that growth.

The most resilient companies are likely to be those able to fund investment from operating cash flow, secure long-duration customers and demonstrate that new capacity will earn returns comfortably above its financing costs.

More speculative operators may face greater scrutiny, particularly where debt is expensive, customers are concentrated or expected revenue depends on demand that has not yet materialised.

For Australian investors, the lesson extends beyond US technology shares. Local data-centre operators, infrastructure funds, electricity suppliers and property groups are increasingly exposed to the same investment cycle.

Artificial intelligence may remain one of the defining growth themes of the decade. But last week’s correction showed that enthusiasm for the technology does not eliminate financial discipline.

The next stage of the AI boom will be judged not only by computing power, model performance or demand for chips, but by something more traditional: whether the assets being financed can generate enough cash to repay the money borrowed to build them.

Fact box

Nasdaq Composite: Down 4.5 per cent for the week ended October 16, 2026

Philadelphia Semiconductor Index: Down approximately 11.4 per cent

Micron Technology: Down approximately 14.6 per cent

Samsung Electronics: Down approximately 18 per cent

SK Hynix: Down approximately 24 per cent

US September inflation: 3.7 per cent annually

Estimated 2026 AI-related investment-grade issuance: Approximately US$300 billion